Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|August 29, 2018
BMS Appoints New Executive Vice-President and Chief Commercial Officer
Author(s)Pharmaceutical Technology Editors
Bristol-Myers Squibb appointed a new executive vice-president and chief commercial officer from within the company, effective immediately.
Advertisement
On Aug. 28, 2018, Bristol-Myers Squibb (BMS) announced that Christopher Boerner, PhD, has been appointed as executive vice-president and chief commercial officer of the company, effective immediately.
According to BMS, Boerner will lead commercial strategy and execution across all geographies. Boerner will report to Giovanni Caforio, MD, chairman and chief executive officer, and will join the company’s leadership team.
Boerner joined the company in February 2015 as head of the US commercial organization.
Most recently, Boerner was head of international markets at BMS where he was accountable for commercial activities in all ex-US markets. Prior to joining BMS, he served as the executive vice-president of commercial for Seattle Genetics, where he led all commercial activities for the company. Before joining Seattle Genetics, Boerner was with Dendreon Corporation, where he led the marketing team. From 2002 to 2010, he worked at Genentech, a member of the Roche Group, where he served in a variety of commercial roles, including director of marketing on Avastin, director of Avastin franchise strategy, and associate director of oncology market development.
Boerner succeeds Murdo Gordon, who left the company on Aug. 3, 2018, to pursue another opportunity, the company reports.
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Complying with International Pharmacopoeias
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5